<DOC>
	<DOCNO>NCT00004266</DOCNO>
	<brief_summary>OBJECTIVES : I . Establish long-term work relationship clinical investigator Minnesota American Indian community . II . Compare effectiveness lisinopril ( angiotensin-converting enzyme inhibitor ) nifedipine ( calcium channel blocker ) prevent nephropathy vascular disease Minnesota American Indians non-insulin-dependent diabetes mellitus microalbuminuria . III . Compare effectiveness simvastatin ( 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor ) lipid-lowering strategy recommend National Cholesterol Education Program prevent nephropathy vascular disease patient .</brief_summary>
	<brief_title>Study Drugs High Blood Pressure High Cholesterol American Indians With Type 2 Diabetes High Risk Kidney Heart Disease</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients randomly assign 1 4 treatment group ; therapy continue 3 year . All patient receive instruction diet , exercise , smoke cessation . The first group receive daily nifedipine dose adjust high blood pressure . Cholestyramine gemfibrozil administer per National Cholesterol Education Program guideline . Diuretics doxazosin may give concurrently . The second group receive daily lisinopril dose adjust high blood pressure . Cholestyramine gemfibrozil administer per National Cholesterol Education Program guideline . Diuretics doxazosin may give concurrently . The third group receive daily nifedipine dose adjust high blood pressure , simvastatin dose adjust high low-density lipoprotein . Supplemental cholestyramine may give need . If cholestyramine tolerate triglyceride high , gemfibrozil substitute cholestyramine . The fourth group receive lisinopril dose adjust high blood pressure simvastatin dose adjust high low-density lipoprotein .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<mesh_term>Lisinopril</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Noninsulindependent diabetes mellitus document fast hyperglycemia Microalbuminuria OR clinically detectable albuminuria ; Urine albumin excretion rate least 30 mg/24 hour Lowdensity lipoproteins ( fast ) least 80 mg/dL Recruitment American Indian population Red Lake Leech Lake reservation Prior/Concurrent Therapy At least 5 day since antihypertensive antilipemics Patient Characteristics Renal : Urine albumintocreatinine ratio least 30 mg/g ; Creatinine clearance estimate creatinine clearance least 30 mL/min ; No active urine sediment suggestive glomerulonephritis , i.e . : No RBCs great 10/highpower field ; No WBCs great 15/highpower field ; No RBC cast Cardiovascular : No symptomatic orthostatic hypotension ; No poorlycompensated congestive heart failure ; No requirement angiotensinconverting enzyme inhibitor ; No angina pectoris require nifedipine ; No unstable angina ; No episodes angina occur month ; No chest pain undetermined cause within 1 month ; No severe hypertension require multiple antihypertensive ; No myocardial infarction within 1 year ; No stroke transient ischemic attack within 1 year Other : No know allergy nifedipine , lisinopril , simvastatin ; No untreated proliferative retinopathy ; Documented retinal exam within 1 year prior entry ; No alcohol drug abuse affect compliance ; No debilitate acute illness ; No pregnant nursing woman ; Effective contraception require fertile woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>diabetic nephropathy</keyword>
	<keyword>rare disease</keyword>
	<keyword>renal genitourinary disorder</keyword>
</DOC>